HONG KONG – With its latest deal to market vitamin D3 in Greater China, Lee's Pharmaceutical Holdings Ltd. is continuing along a growth path that has helped the company more than triple its share price in three years.
HONG KONG – The world's largest health care-dedicated investment firm, Orbimed, has secured a $325 million pan-Asia fund to invest in health care markets in the region, particularly in China and India.
HONG KONG – With its latest deal to market vitamin D3 in Greater China, Lee's Pharmaceutical Holdings Ltd. is continuing along a growth path that has helped the company more than triple its share price in three years.
HONG KONG – As researchers around the world speed up their efforts to develop and register new and more effective treatments for Ebola, China announced the approval of its first drug against the fatal virus for emergency use.
HONG KONG – As researchers around the world speed up their efforts to develop and register new and more effective treatments for Ebola, China announced the approval of its first drug against the fatal virus for emergency use.
HONG KONG – Just one month after its $764 million initial public offering (IPO) in Hong Kong, leading Chinese pharmaceutical company Luye Pharma took a significant expansionary step with the acquisition of Beijing Jialin Pharmaceutical.
HONG KONG – Just one month after its $764 million initial public offering (IPO) in Hong Kong, leading Chinese pharmaceutical company Luye Pharma took a significant expansionary step with the acquisition of Beijing Jialin Pharmaceutical.
